Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
The objective of this study is to estimate the median progression-free survival for patients receiving this regimen, along with the rate of complete response at 6 months, toxicities associated with this regimen, and laboratory correlates. Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression.
Patients with biopsy-proven non-hodgkins lymphoma of follicular grade 1, 2, or 3 Meeting FLIPI criteria for intermediate or high risk. No prior chemotherapy, radiotherapy or immunotherapy for lymphoma; Patients may not have known HIV infection, and must not be Hepatitis B Surface Antigen positive.
Exclusion Criteria:
May not be pregnant or breastfeeding, have documented CNS (Central Nervous System) disease, G-CSF (Granulocyte Colony Stimulating Facto) or GM-CSF (Granulocyte/Macrophage Colony Stimulating Factor) within 2 weeks prior
